Connect with us


2,000 Extra Nursing Associates Expected in 2018



Health Education England has said that at least a further 2,000 people are expected to be trained as nursing associates in the NHS and social care during 2018.

Leaders at Health Education England (HEE) have vowed to provide at least an extra 2000 places for students wanting to train as Nursing Associates. This will be in addition to the posts that already been announced.

This follows the formal release of the Nursing Associate Trainee job description and news that the new role will be subject to regulation by the Nursing and Midwifery Council (NMC).

The aim of the pilot is to create a new generation of nursing staff that will bridge the gap between healthcare assistants and registered nurses.

Although the role has been a the source of heavy criticism Health Education England feel Nursing Associates might be the answer to the looking staffing crisis.

Tom Sandford, director of the Royal College of Nursing in England, says “We are very worried they are going to be a nursing workforce on the cheap. We want to understand more about the training. It is endemic in the public sector. It is not just in nursing, in almost every area of public service they are looking for substitution cheaper labour“.

You can view the Department of Health’s Infographic on ‘Route into Nursing‘, which was released following the announcement explaining how Nursing Associates can “top-up” to a degree in order to become a Registered Nurse. 

Continue Reading
Join the discussion...

Leave a Reply

Your email address will not be published. Required fields are marked *


Royal College of Midwives to end campaign to promote ‘normal births’




The Royal College of Midwives ends their campaign for “normal births” to avoid making mothers who opt for medical interventions feel like failures.

The Royal College of Midwives (RCM) has been running a continuous campaign since 2005 to encourage expectant mothers to give birth without medical interventions such as; epidurals, inductions and caesareans.

Currently, around 40% of mothers give birth without medical interventions. 20% less than 30 years ago. But experts say a significant number of these are due to the increase in more risky pregnancies.

Prof Cathy Warwick, the Chief Executive of the RCM, said;

“There was a danger that if you just talk about normal births – and particularly if you call it a campaign – it kind of sounds as if you’re only interested in women who have a vaginal birth without intervention”.

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately, that seems to be how some women feel.”

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately that seems to be how some women feel.”

Midwives, will instead, start to use the term “physiological births” to describe those without interventions.

Continue Reading


Pancreatic cancer patients to have routine access to life extending drug after new deal



NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and provided more evidence on its effectiveness.

Nab-paclitaxel, also known as Abraxane, made by Celgene will be routinely available as an option for patients with pancreatic cancer that has progressed.

When Abraxane is added to a standard chemotherapy, called gemcibatine the evidence has found it extends life by an average of 2.4 months.

If other combination chemotherapy treatments are unsuitable for a patient, NICE recommends offering Abraxane instead of this standard chemotherapy on its own.

It works by blocking the action of the proteins within cancer cells that cause them to grow and divide.

NICE has reviewed its guidance from 2015 which did not recommend Abraxane for routine NHS use for not being cost-effective.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: The life expectancy of pancreatic cancer is poor, with patients usually living for only up to 6 months. It’s incredibly important that patients and families affected by this disease are able to have routine access to this life extending treatment.”

There are almost 10,000 new cases of pancreatic cancer each year in the UK, and less than 1% survive for 10 or more years.

This is a final appraisal determination for Abraxane. The company, healthcare professionals and patient/carer organisations now have until Friday 1 September to appeal the decision.

Continue Reading